1,2-Diarylimidazoles as inhibitors of cyclooxygenase-2: a quantitative structure-activity relationship study.

The cyclooxygenase-2 (COX-2) enzyme inhibition activity of derivatives of 1,2-diarylimidazole is analysed through Fujita-Ban and Hansch approaches. The analyses have helped to ascertain the role of different substituents in explaining the observed inhibitory potency of these analogues. From both approaches it is revealed that the more hydrophobic X-substitutions that are present at the 3- and 4-positions of the aryl ring and are also non-hydrogen acceptor in character improve inhibitory action of a compound. The smaller substituent either H or F is preferred at the 2-X position as it is involved in steric interaction. Likewise, the substituent-NH2 instead of Me at R is advantageous. Further, for a data set of 35 congeners, the selectivity ratio related to the constitutive COX-1 isozyme is also analysed through the Fujita-Ban approach. The derived contributions of parent moiety and various substituents have helped to predict the substitution pattern in the design of more effective compounds that were not in the original data set.

[1]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[2]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[3]  T. Fujita,et al.  Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters. , 1971, Journal of medicinal chemistry.

[4]  J. Smith,et al.  Aspirin selectively inhibits prostaglandin production in human platelets. , 1971, Nature: New biology.

[5]  A. Leo,et al.  Substituent constants for correlation analysis in chemistry and biology , 1979 .

[6]  D M Clive,et al.  Renal syndromes associated with nonsteroidal antiinflammatory drugs. , 1984, The New England journal of medicine.

[7]  J. Lombardino Nonsteroidal antiinflammatory drugs , 1985 .

[8]  Y. Pirson,et al.  Renal side effects of nonsteroidal antiinflammatory drugs: clinical relevance. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  R. Erikson,et al.  Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[11]  C. Torrance,et al.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. , 1992, The New England journal of medicine.

[12]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Seibert,et al.  Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Koboldt,et al.  1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. , 1997, Journal of medicinal chemistry.

[16]  R. Kumar,et al.  Novel inhibitors of cyclooxygenase-2: the sulfones and sulfonamides of 1,2-diaryl-4,5-difluorobenzene. Analysis of quantitative structure-activity relationship. , 1998, Journal of enzyme inhibition.